SOPHiA GENETICS is tasked with developing its Solid Tumor application as a decentralised companion diagnostic.

Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows ...

Now a new study suggests that, for some of us, our muscles may get a boost from Neanderthal genetics.

Key Points Interested in SOPHiA GENETICS SA? Here are five stocks we like better. Q2 revenue rose 27% to $23.3 million, while ...

Genetics is the study of genes and how they influence characteristics and health. Through a variety of technological methods, environmental factors, and lifestyle choices, it is possible to alter some ...

View SOPHiA GENETICS SA SOPH stock quote prices, financial information, real-time forecasts, and company news from CNN.

How much do your genes and upbringing determine your success? A landmark Norwegian study untangles the complex interplay between genetics, family, and social policies in shaping who thrives. Study: ...

Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging ...

Myriad Genetics lowered its full-year revenue guidance, as second quarter sales fell due to volume challenges in prenatal health and increased payer friction. The genetic testing and precision ...

SOPHiA GENETICS President and CEO Ross Muken discusses the use of AI and technology in diagnosing and treating patients, particularly those with cancer.

Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% ...